"No significant differences between placebo and PXS-6302 treatment groups were observed in Patient Observer Scar Assessment Scale (POSAS) scores at study conclusion."
That was the critical conclusion IMV which was rather disappointing to us all ,and was partly responsible for the poor share price performance subsequently .
I'd always assumed the scar would look cosmetically better afterwards if 6302 was working (which it obviously was!)
I've thought since then that Syntara is much better focussed on fibrosis elsewhere.
And so far results seem to bear that out .
Add to My Watchlist
What is My Watchlist?
